Virus Manufacturing Service
GMP viral manufacturing for lentivirus, retrovirus, AAV, adenovirus, and oncolytic viruses — supporting gene therapy, vaccines, and cell-based therapies.
Key advantages:
-
High titer: Purified virus achieves high titers, e.g., lentivirus up to 109 TU/ml.
-
High quality: High transduction efficiency with low impurity levels, meeting clinical standards and reaching domestic leading and internationally advanced levels.
-
Safety: Strict safety controls applied from vector design to material usage.
-
Advanced technology: Core processes utilize internationally recognized imported equipment.
Viral vector production is a critical step in the development of cell and gene therapy products, and remains one of the major bottlenecks for commercialization.
Our viral vector platform has established advanced production technologies for high-yield lentivirus, retrovirus, AAV, adenovirus, and oncolytic viruses, supported by a comprehensive quality control system that fully meets clinical standards.
The platform is designed to accelerate the development of gene-modified cell therapies and gene therapies, while providing more cost-effective and scalable viral vector manufacturing solutions for the latest advances in the field.
Get in Touch
We’re here to answer your questions and explore potential collaborations.